Arg164
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Mono-methylation Site Page: > Arg164  -  Pur-beta (mouse)

Site Information
RIRQTVNrGGGGFGG   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 8092933

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 )
Disease tissue studied:
testicular cancer ( 22 )
Relevant cell line - cell type - tissue:
'brain, embryonic' ( 28 ) , brain ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 27 ) , embryo ( 1 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 ) , F9 (testicular) ( 22 ) , heart ( 29 ) , kidney ( 23 , 25 ) , liver ( 30 ) , lung ( 24 , 26 ) , PYS-2 (epithelial) ( 21 )

References 

1

Guo A, et al. (2014) Immunoaffinity enrichment and mass spectrometry analysis of protein methylation. Mol Cell Proteomics 13, 372-87
24129315   Curated Info

2

Guo A (2013) CST Curation Set: 18332; Year: ; Biosample/Treatment: tissue, brain/-; Disease: -; SILAC: -;
Curated Info

3

Guo A (2013) CST Curation Set: 18333; Year: ; Biosample/Treatment: tissue, brain/-; Disease: -; SILAC: -;
Curated Info

4

Guo A (2013) CST Curation Set: 18334; Year: ; Biosample/Treatment: tissue, brain/-; Disease: -; SILAC: -;
Curated Info

5

Guo A (2013) CST Curation Set: 18335; Year: ; Biosample/Treatment: tissue, brain/-; Disease: -; SILAC: -;
Curated Info

6

Guo A (2013) CST Curation Set: 18336; Year: ; Biosample/Treatment: tissue, brain/-; Disease: -; SILAC: -;
Curated Info

7

Guo A (2013) CST Curation Set: 18337; Year: ; Biosample/Treatment: tissue, brain/-; Disease: -; SILAC: -;
Curated Info

8

Guo A (2013) CST Curation Set: 18338; Year: ; Biosample/Treatment: tissue, embryo/-; Disease: -; SILAC: -;
Curated Info

9

Guo A (2013) CST Curation Set: 18339; Year: ; Biosample/Treatment: tissue, embryo/-; Disease: -; SILAC: -;
Curated Info

10

Guo A (2013) CST Curation Set: 18340; Year: ; Biosample/Treatment: tissue, embryo/-; Disease: -; SILAC: -;
Curated Info

11

Guo A (2013) CST Curation Set: 18341; Year: ; Biosample/Treatment: tissue, embryo/-; Disease: -; SILAC: -;
Curated Info

12

Guo A (2013) CST Curation Set: 18342; Year: ; Biosample/Treatment: tissue, embryo/-; Disease: -; SILAC: -;
Curated Info

13

Guo A (2013) CST Curation Set: 18343; Year: ; Biosample/Treatment: tissue, embryo/-; Disease: -; SILAC: -;
Curated Info

14

Guo A (2013) CST Curation Set: 18344; Year: ; Biosample/Treatment: tissue, embryo/-; Disease: -; SILAC: -;
Curated Info

15

Guo A (2013) CST Curation Set: 18345; Year: ; Biosample/Treatment: tissue, embryo/-; Disease: -; SILAC: -;
Curated Info

16

Guo A (2013) CST Curation Set: 18346; Year: ; Biosample/Treatment: tissue, embryo/-; Disease: -; SILAC: -;
Curated Info

17

Guo A (2013) CST Curation Set: 18347; Year: ; Biosample/Treatment: tissue, embryo/-; Disease: -; SILAC: -;
Curated Info

18

Guo A (2013) CST Curation Set: 18348; Year: ; Biosample/Treatment: tissue, embryo/-; Disease: -; SILAC: -;
Curated Info

19

Guo A (2013) CST Curation Set: 18349; Year: ; Biosample/Treatment: tissue, embryo/-; Disease: -; SILAC: -;
Curated Info

20

Zhou J (2010) CST Curation Set: 9110; Year: 2010; Biosample/Treatment: cell line, ES J1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R
Curated Info

21

Zhou J (2010) CST Curation Set: 9115; Year: 2010; Biosample/Treatment: cell line, PY2/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R
Curated Info

22

Zhou J (2010) CST Curation Set: 9111; Year: 2010; Biosample/Treatment: cell line, F9/untreated; Disease: testicular cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R
Curated Info

23

Zhou J (2009) CST Curation Set: 7948; Year: 2009; Biosample/Treatment: tissue, kidney/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R
Curated Info

24

Zhou J (2009) CST Curation Set: 7946; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R
Curated Info

25

Zhou J (2009) CST Curation Set: 7947; Year: 2009; Biosample/Treatment: tissue, kidney/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R
Curated Info

26

Zhou J (2009) CST Curation Set: 7945; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R
Curated Info

27

Zhou J (2008) CST Curation Set: 3811; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R
Curated Info

28

Zhou J (2008) CST Curation Set: 3812; Year: 2008; Biosample/Treatment: tissue, brain, embryonic/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R
Curated Info

29

Zhou J (2008) CST Curation Set: 3813; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R
Curated Info

30

Zhou J (2008) CST Curation Set: 3814; Year: 2008; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R
Curated Info